Saturday, January 02, 2021 1:21:13 AM
BioClonetics Proprietary mAb Methodologies & Immunotherapeutic Technologies Platform for Therapeutics
Biologics, specifically, fully human neutralizing monoclonal antibodies directed against infectious disease, are considered the new frontier in biotechnology. In the past, the initial starting products were “humanized” rat and mouse mAbs being created for therapeutic use.
"Humanized” immunoglobulins are the major immunotherapeutics that are prevalent today. What sets BioClonetics' antibody technology apart from everyone else’s? Our organization has the capacity to clone the human or animal immune system cells. With BioClonetics' proprietary methodologies, stable parent hybridomas cell lines can be created that produce fully human (or animal) antibodies.
BioClonetics specializes in creation of human neutralizing monoclonal antibodies, not "humanized" mouse or rat counterparts, as are the majority of mAb therapeutics in pharmaceutical use today. BioClonetics’ technological methodologies have developed an effective, strong and robust portfolio of biologics that have pharmaceutical application with significant benefits to patients or animals in the global marketplace. From an identified and created parent hybridoma cell line, four distinct and effective products can be produced: (1) fully human neutralizing monoclonal antibody—directed against any pathogen based disease entity—through use in passive immunotherapy; (2) an effective humoral active vaccine that is safe and effective; (3) an oral mini-antibody peptide based medication with an efficacy that is equivalent to the immunologic capacity of the monoclonal antibody produced by parent hybridoma cell; and (4) an entry-fusion inhibitor that is immunologic in character and scope. The applications are broad, effective and beneficial for immunotherapeutic use.
The methodologies and processes for creating immortalized cells that stably produce human monoclonal antibodies is a company proprietary trade secret. BioClonetics is amenable to discussing licensing the innovational technique of cloning the immune system of any species in the animal kingdom
Recent ENZC News
- Small Cap Recipient of Military Drone Technology • InvestorsHub NewsWire • 11/20/2023 01:14:45 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM